Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.2750 16/02/17
52 week low0.6760 08/12/16
52 week change -0.1500 (-17.14%)
4 week volume252,330,489 24/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Placing

RNS Number: 4679W Sareum Holdings PLC 14 November 2017 (AIM: SAR) 14 November 2017 Sareum Holdings plc ("Sareum" or "the Company") Placing Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces that it has raised 700,000, before expenses, through a placement via Hybridan LLP as agent of the Comp...

Sareum notes experiment progress

Sareum Holdings has noted that Sierra Oncology, the licence holder advancing a clinical cancer candidate Chk1 inhibitor, r...

Sierra Reports Preclinical Data for Chk1 Inhibitor

RNS Number: 0638V Sareum Holdings PLC 31 October 2017 (AIM: SAR) 31 October 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy - SRA737 demonstrates synergy with replication stress-inducing agents - - SRA737 plus gemci...

Sareum reports maiden profit of £400,000

Sareum, a cancer drug discovery and development company, made a maiden profit after tax on ordinary activities of 400...

Final Results

RNS Number: 9927T Sareum Holdings PLC 19 October 2017 (AIM: SAR) 19 October 2017 Sareum Holdings plc ("Sareum" or "the Company") Final Results Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development company , announces its final results for the year ended 30 June 2017. Operational highlights Lead cancer drug candidate SRA...

Sierra Oncology host KOL Meeting on 12 Oct in NY

RNS Number: 0604T Sareum Holdings PLC 09 October 2017 (AIM: SAR) 9 October 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY Sareum Holdings plc (AIM: SAR) , th...

Sierra Oncology to host call on Chk1 inhibitor

RNS Number: 0247R Sareum Holdings PLC 18 September 2017 (AIM: SAR) 18 September 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology to host Key Opinion Leader call with Thomas Helleday, PhD on DNA Damage Response Targets, on Tuesday 19 September Sareum Holdings plc (AIM: SAR) , the specialist cancer drug discovery an...

Sareum profit after tax anticipated to beat expectations

Sareum said it expects profit for the year after tax and cash at bank, for its results for the year to 30 June 2017, to be ahead...

Fundamental DataMore

P/E ratio36.25
EPS0.02
Dividend yield0 %

Latest discussion posts More

  • Re: Good progress & maiden profits

    http://uk.advfn.com/p.php?pid=chartscreenshotshow&u=CTcwOoFJTTlWkejW+geWUhtoFp3NOSgnWPFmM8wjkZQ= Posted this chart in October - been waiting for 0.75p entry price since then ...
    16-Nov-2017
    KALAN
  • Re: Another 200% up....

    Cornhill had this for a week .
    15-Nov-2017
    Ripley94
  • Re: Another 200% up....

    RNS placing @ 7p Share price dropped 14%...... to 7.5p to 8p. British Bulls were correct maybe does show in chart. Again Aim all about placings at a discount.
    14-Nov-2017
    Ripley94

Users' HoldingsMore

Users who hold Sareum Holdings also hold..
RANGE RES.17%
LLOYDS GRP.16%
SOLO OIL12%
ROCKHOPPER12%
VALIRX11%

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account